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Implications for Cardiac Function 
Following Rescue of the Dystrophic 
Diaphragm in a Mouse Model of 
Duchenne Muscular Dystrophy
Corinne A. Betts1, Amer F. Saleh2,3, Carolyn A. Carr1, Sofia Muses4, Kim E Wells4, 
Suzan M. Hammond1, Caroline Godfrey1, Graham McClorey1, Caroline Woffindale1, 
Kieran Clarke1, Dominic J Wells4, Michael J. Gait2 & Matthew J. A. Wood1
Duchenne muscular dystrophy (DMD) is caused by absence of the integral structural protein, 
dystrophin, which renders muscle fibres susceptible to injury and degeneration. This ultimately 
results in cardiorespiratory dysfunction, which is the predominant cause of death in DMD patients, 
and highlights the importance of therapeutic targeting of the cardiorespiratory system. While there 
is some evidence to suggest that restoring dystrophin in the diaphragm improves both respiratory 
and cardiac function, the role of the diaphragm is not well understood. Here using exon skipping 
oligonucleotides we predominantly restored dystrophin in the diaphragm and assessed cardiac 
function by MRI. This approach reduced diaphragmatic pathophysiology and markedly improved 
diaphragm function but did not improve cardiac function or pathophysiology, with or without 
exercise. Interestingly, exercise resulted in a reduction of dystrophin protein and exon skipping in the 
diaphragm. This suggests that treatment regimens may require modification in more active patients. 
In conclusion, whilst the diaphragm is an important respiratory muscle, it is likely that dystrophin 
needs to be restored in other tissues, including multiple accessory respiratory muscles, and of course 
the heart itself for appropriate therapeutic outcomes. This supports the requirement of a body-wide 
therapy to treat DMD.
Cardiac and respiratory complications are the leading cause of death amongst Duchenne muscular dys-
trophy (DMD) patients1,2. DMD is a debilitating muscle wasting disorder, caused by mutations/dele-
tions in the Dmd gene which disrupts the reading frame and prevents the translation of dystrophin 
protein3–5. Dystrophin is an important sarcolemmal protein which stabilises the sarcolemma6, and thus 
dystrophin-deficient muscles are particularly susceptible to contraction-induced damage and muscle 
fibres are replaced with fibrous connective tissue and fat rendering the muscle ineffective7,8. Indeed it 
is the deposition of fibrous tissue and further deterioration of the diaphragm which contributes sig-
nificantly to respiratory insufficiency9. In addition, impaired respiration compromises cardiac function 
due to increased pulmonary hypertension which eventually leads to dilated cardiomyopathy10. Other 
symptoms of cardiomyopathy in DMD patients include tachycardia, electrocardiogram (ECG) abnor-
malities, left ventricle thickening (hypertrophy) and a decrease in fractional shortening11,12. It should be 
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noted that splice-switching oligonucleotide (SSO) therapies currently undergoing clinical trial, namely 
phosphorodiamidate morpholino oligomer and 2’O methyl phosphorothioate oligonucleotides, are not 
capable of restoring dystrophin in the heart13–16. Therefore it is essential to address the contribution of 
other important muscles, such as the diaphragm to cardiorespiratory function.
Improvement in cardio-respiratory function in DMD patients would enhance quality of life and pre-
vent fatal complications. Two independent studies have proposed that the restoration of dystrophin in 
the diaphragm of DMD mouse models has a profound beneficial effect on respiratory17 and cardiac 
function18. If this were indeed the case, it would lessen the requirement for treating the heart, which is 
an especially difficult tissue to target. However, neither study completely answers the question as to what 
extent restoring dystrophin to the dystrophic diaphragm is able to improve cardiac function. The study 
which assessed respiratory function showed that specific restoration of dystrophin in the diaphragm 
using a helper-dependent adenovirus vector, increased tidal volume and improved compensatory hyper-
pnea17. However, neither cardiac function nor cardiac histopathology were assessed in this study. The 
second study did assess cardiac function, but dystrophin was restored in multiple muscles including skel-
etal muscles and accessory respiratory muscles and therefore the contribution of a rescued diaphragm 
exhibiting physiological improvement could not be assessed18.
To address the role of the diaphragm, we predominantly restored dystrophin in the diaphragm of mdx 
mice using an exon skipping approach via use of SSO-peptide conjugates, and measured the effect of the 
rescued diaphragmatic dystrophin expression and function on cardiac function, using MRI. Increased 
activity has also been shown to contribute to a progressed cardiac phenotype19, and therefore we also 
assessed whether restoration of dystrophin in the diaphragm is capable of rescuing cardiac function in 
the presence of forced exercise. In short, the intraperitoneal route of administration resulted in substan-
tial dystrophin restoration to the diaphragm and abdominal wall muscles (due to proximity of admin-
istration site), and low to negligible levels of dystrophin protein in sternocleidomastoid and intercostal 
muscles. The restoration of dystrophin in the diaphragm markedly improved diaphragmatic physiology, 
notably specific force and resistance to eccentric exercise induced force drop, and reduced pathophysi-
ology of this muscle, but did not have a beneficial effect on cardiac function or cardiac pathophysiology, 
with or without exercise. In addition, there was significantly less dystrophin restored to the diaphragm 
of treated, exercised mdx mice.
Results
Intravenous Peptide-PMO administration Restores Dystrophin in Additional Respiratory 
Muscles. It has previously been demonstrated that a single intravenous administration of phospho-
rodiamidate morpholino oligonucleotides (PMO), conjugated to an arginine-rich (RXRRBR)2 peptide 
(B-peptide), improves cardiac function in mdx mice18,20. The authors attributed this to the restoration of 
dystrophin to the diaphragm18. However, it is known that intravenous administration of peptide-PMO 
conjugates results in highly efficient body-wide skeletal muscle delivery and dystrophin restoration21, 
whereas intraperitoneal administration results predominantly in diaphragmatic dystrophin restoration22. 
It is therefore likely that the intravenous route of administration restored dystrophin in other muscles 
such as respiratory muscles. To determine any differences in dystrophin restoration between the two 
administration routes, a single 19 mg/kg dose (as used in Crisp et al.18) was delivered either intrave-
nously via the tail vein or via the intraperitoneal route, and tissues were harvested 3 weeks later (Fig. 1). 
Intravenous administration of B-PMO resulted in widespread and high levels of dystrophin restora-
tion in major respiratory muscles including the diaphragm, intercostal and sternomastoid muscles. As 
expected, the intraperitoneal administration resulted in marked dystrophin restoration in the diaphragm, 
but with very low levels of dystrophin in the intercostal and sternomastoid muscles, thus demonstrating 
the marked disparity between the two delivery routes. Neither administration route resulted in dystro-
phin restoration in heart at the dose used.
Substantial Dystrophin Restoration in Diaphragm Following Intraperitoneal Administration. 
Accessory respiratory muscles may also facilitate respiratory function, and therefore the intravenous 
administration route does not demonstrate the specific impact of a corrected diaphragm in DMD. 
Therefore, building on the comparative route of administration experiment (Fig.  1), a detailed study 
quantifying dystrophin restoration levels and cardiac function following intraperitoneal administration 
of B-PMO, was initiated (21 week old mice administered dose of 19 mg/kg; modelled closely to Crisp 
et al.18). For exercised groups, mice were run the following day, and every second day thereafter for 
3 weeks (10 bouts of exercise in total; Supplementary Fig. S1 online). Tissues were harvested at 24 
weeks of age. Exon skipping and dystrophin protein restoration in the diaphragms of B-PMO treated 
mdx mice were assessed using routine techniques, namely immunohistochemical staining, RT-PCR, 
quantitative real time-PCR (RT-qPCR) and western blotting. Additional tissues assessed for dystrophin 
restoration included the heart, tibialis anterior, abdominal wall, intercostal muscles and sternomastoid 
muscles. Immunohistochemical staining for dystrophin in the B-PMO treated cohorts revealed exten-
sive dystrophin expression in the diaphragm (Fig. 2a), which is illustrated by the box plots showing the 
normalised relative intensity values for each region of interest. The distribution pattern of the B-PMO 
treated cohorts correlates with the C57BL/10 cohorts (Fig. 2b). Dystrophin expression was very low in 
the tibialis anterior, intercostal and sternomastoid muscles and completely absent in the heart (Fig.  2; 
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similar distribution patterns to mdx). Intraperitoneal administration also resulted in dystrophin expres-
sion in the abdominal wall muscle, which is not surprising given the proximity of the administration site. 
The RT-PCR and western blots revealed complete exon skipping of dystrophin (Fig. 3a) and substantial 
dystrophin protein restoration in the diaphragms of B-PMO treated mice (unexercised 41%, exercised 
16%; Fig. 3b and Supplementary Fig. S2 online). Splicing efficiency in the diaphragms of B-PMO treated 
mice was confirmed by RT-qPCR which resulted in 91% and 79% exon 23 exclusion in unexercised and 
exercised mice, respectively (Fig.  3c). Dystrophin splicing levels in the tibialis anterior, intercostal and 
sternomastoid muscles were low, with approximately 1% dystrophin protein restoration in the tibialis 
anterior and sternomastoid muscles, and 4% restoration in intercostal muscles. Dystrophin splicing and 
protein restoration was absent in the hearts of B-PMO treated mice. High dystrophin splicing levels 
(unexercised 49%, exercised 72%; Fig. 3c) and marked protein restoration (unexercised 30%, exercised 
36%; Fig. 3b) were also observed in the abdominal wall muscles of B-PMO treated mice.
Interestingly there was a significant disparity in dystrophin protein restoration (measured by western 
blot; Fig.  3b) in the diaphragms of unexercised and exercised B-PMO treated mdx mice (p < 0.05). A 
reduction in dystrophin splicing was also observed in exercised treated mice when considering RT-qPCR 
data (i.e. 91% versus 79% exon 23 exclusion).
Rescue of Diaphragmatic Dystrophin Does Not Improve Cardiac Function. Mice underwent 
MRI at 24 weeks of age. All cardiac parameters were normalised to weight (with the exception of the 
ejection fraction (EF) which is the volumetric fraction of blood pumped from each ventricle after each 
heartbeat and is independent of weight). Cardiac function of the unexercised mdx and unexercised 
Figure 1. Immunohistochemical staining of dystrophin comparing B-PMO treatment following 
intravenous and intraperitoneal administration. Representative images of dystrophin staining for 
diaphragm, heart, intercostal muscles and sternomastoid muscles are shown. C57BL/10 and untreated mdx 
muscles were compared to mdx mice treated by intravenous and intraperitoneal routes of administration. 
For treated groups, mice received a single 19 mg/kg injection. Figure illustrates restoration of dystrophin 
in diaphragm and respiratory muscles, the intercostal and sternomastoid muscles, when B-PMO was 
administered intravenously. However dystrophin was only prevalent in diaphragm following intraperitoneal 
administration.
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B-PMO treated cohorts was compared with that of their C57BL/10 counterpart (n = 10 for each cohort). 
The unexercised mdx cohort revealed lower left ventricular cardiac output (LV CO) and changes in a 
number of right ventricle (RV) measurements, relative to unexercised C57BL/10 mice (Fig. 4). RV stroke 
volume (SV) was lowered, with subsequent reduction in EF and CO suggesting impaired contractility. 
Similarly, the unexercised B-PMO treated mice also exhibited low LV SV and CO, and changes in mul-
tiple RV parameters relative to unexercised C57BL/10 (Fig. 4 and Table 1). This indicates that significant 
restoration of dystrophin protein in the diaphragm and abdominal wall muscles (B-PMO unexercised 
mice) did not improve cardiac function.
Exercised cohorts were also included in the study to determine whether dystrophin in the diaphragm 
can prevent deterioration of the cardiac phenotype in mdx mice, in the event of exercise. These mice 
underwent 10 bouts of forced exercise over the course of 3 weeks. The exercise had a significant effect 
on the untreated mdx mouse hearts for a number of cardiac measurements, as determined by Two-way 
ANOVA (see Table  1 for interaction effects). The mdx exercised cohort revealed lowered LV SV and 
increased RV end systolic volume with consequential decrease in RV EF (see Table  1 for significance 
between unexercised and exercised mdx cohorts). This suggests that exercise resulted in further dete-
rioration of RV contractility in mdx mice. In contrast, the C57BL/10 and B-PMO treated cohorts were 
largely unchanged by exercise (see Table 1 for significance relative to exercised counterpart).
Direct comparison of the mdx exercised cohort with its C57BL/10 counterpart revealed significant 
changes in LV SV and LV CO (Fig. 5 and Table 1). The mdx group also revealed pronounced changes in 
a number of RV parameters relative to the C57BL/10 counterpart. Although the B-PMO treated cohort 
did not deteriorate with exercise, this group revealed similar cardiac function parameter values to the 
mdx exercised cohort (LV SV, LV CO lower, RV SV and RV CO lower than the C57BL/10). Therefore the 
Figure 2. Immunohistochemical staining and quantification of dystrophin following B-PMO treatment 
delivered via intraperitoneal route of administration. (a) Representative images of immunohistochemical 
staining of dystrophin protein in exercised and unexercised C57BL/10, mdx and B-PMO treated mdx mice 
showing the diaphragm, heart, tibialis anterior, intercostal muscles, sternomastoid muscles and abdominal 
wall. Tissues were harvested 3 weeks after B-PMO administration (19 mg/kg administration). (b) Dystrophin 
immunohistochemical staining quantification following B-PMO treatment in mdx mice. Dystrophin 
expression was calculated relative to laminin co-stain (120 regions of interest per slide), and normalised 
relative to the C57BL/10 unexercised group. The box plots show the normalised relative intensity values for 
each region of interest, and the distribution pattern thereof. N = 4 for each cohort.
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B-PMO treatment and rescue of dystrophin expression in the diaphragm and abdominal wall muscles 
did not protect heart function in the event of exercise.
Restoration of Diaphragmatic Dystrophin Markedly Improves Muscle Function. To assess the 
functional effects of B-PMO administration on the diaphragm, we treated 21-week old male mdx (n = 7) 
with a single intraperitoneal injection of B-PMO (19 mg/kg). Age and litter matched male mdx mice 
were used as controls (n = 8). Three weeks post-treatment we evaluated the force-frequency relationship 
between the two groups. A significant improvement in specific force (N/cm2) was noted over a range 
of stimulation frequencies (30 Hz-180 Hz) in the B-PMO treated mice (Fig.  6a). In addition, a single 
dose of B-PMO improved maximal specific isometric force by 88% (13.94 ± 0.69 N/cm2) compared to 
non-treated controls (7.4 ± 1.26 N/cm2). Using a muscle eccentric contraction protocol with 10% stretch, 
we measured resistance to eccentric contraction-induced muscle damage. Diaphragms from B-PMO 
Figure 3. Dystrophin splicing and protein restoration in B-PMO treated mice compared to mdx 
untreated and C57BL/10 control groups. (a) Representative images of reverse-transcriptase (RT) PCR 
illustrating exon 23 exclusion in diaphragm, heart, tibialis anterior (TA), intercostal muscles, sternomastoid 
muscles and abdominal wall of B-PMO treated cohort. The top band represents full length dystrophin (FL) 
and the lower band represents the skipped transcript (Skipped). (b) Protein quantification of western blots 
in diaphragm, TA, intercostal and sternomastoid muscles of B-PMO treated mice. 10–15 μ g of protein was 
loaded and quantified relative to vinculin loading control. Average values and SEM are as follows: diaphragm 
unexercised: 41% SEM 3.9, exercised: 17% SEM 4.3; TA unexercised: 1% SEM 0.3, exercised: 0.5% SEM 0.1); 
intercostal unexercised: 5% SEM 0.6, exercised: 4% SEM 0.8; sternomastoid muscles unexercised: 0.8% SEM 
0.3, exercised: 0.9% SEM 0.3; and abdominal wall unexercised: 30% SEM 6.8, exercised: 36% SEM 7.8. Note: 
no protein was detected in hearts of B-PMO treated mice (See Supplementary Fig. S2 online). (c) RT-qPCR 
was also performed on diaphragm and abdominal wall samples and confirmed exemplary exon 23 exclusion. 
N = 4 for each cohort. Statistical significance was determined using Students T-test (p < 0.05).
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treated mice exhibited significant protection against eccentric contraction-induced muscle damage, from 
contraction number four to ten, in contrast to untreated controls (Fig. 6b). A final tetanic force loss of 
6.7 ± 0.87% compared to baseline was observed in the B-PMO treated groups, unlike the control mice 
which exhibited an 18.6 ± 2.55% force drop from baseline. Thus a single intraperitoneal administration 
was sufficient to markedly improve diaphragm function.
Pathophysiological Improvement in Dystrophin-Restored Diaphragm Does Not Ameliorate 
the Cardiac Phenotype. Substantial restoration of dystrophin in the diaphragm also reduced dia-
phragmatic pathophysiology, as shown by reduced Evans blue dye (EBD) leakage into the muscle. EBD 
is a tracer used to determine the extent of sarcolemmal damage as a result of the lack of dystrophin in 
muscle23,24. EBD leakage is markedly elevated in mdx mice, particularly if exercised. The surface area of 
EBD infiltration into the diaphragms of the mdx unexercised and exercised cohorts were both markedly 
greater than the unexercised and exercised C57BL/10 and B-PMO cohorts (Fig. 7a). The B-PMO treated 
mice exhibited a near normalised EBD profile, which was anticipated given the substantial amount of 
dystrophin in the diaphragm, thus improving membrane stability and preventing the infiltration of EBD 
into tissue.
EBD leakage into the tibialis anterior of the mdx exercised mice was significantly higher than all other 
cohorts with the exception of the B-PMO exercised counterpart (mdx exercised cohort: average of 8% 
EBD infiltration; Fig.  7c). The B-PMO exercised cohort also exhibited marked elevation in EBD infil-
tration however to a lesser extent then the mdx exercised cohort. This confirms that the intraperitoneal 
administration did not successfully restore dystrophin in peripheral muscles such as the tibialis anterior, 
to substantially reduce pathophysiology.
Whilst there was no significant EBD leakage into the hearts of any cohort, it should be noted that the 
mdx exercised, B-PMO unexercised and B-PMO exercised cohorts all exhibited slightly elevated levels 
of infiltration. Indeed one of the B-PMO exercised mice displayed marked EBD leakage (see Fig. 7b and 
Figure 4. Cardiac function parameters measured by cine-MRI in unexercised mouse cohorts. Scatter plot 
graphs illustrating individual mouse values, mean and standard error of the mean (SEM) for left ventricular 
(LV) and right ventricular (RV) functional parameters relative to body weight. Note: The exception to this 
was the ejection fraction which was represented as a percentage (it is a volumetric fraction). B-PMO and 
mdx cohorts exhibited worse cardiac function than C57BL/10 mice. Statistical significance was determined 
using ANOVA followed by Tukey post-hoc test or Games-Howell post-hoc test to correct for variance 
heterogeneity. (***p < 0.001, **p < 0.01, *p < 0.05). N = 10 for each cohort.
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Supplementary Fig. S3 online). In addition, there was no reduction in the expression of genes indicative 
of cardiac damage. RT-qPCR was carried out on heart tissue to assess the expression of markers for hae-
modynamic overload and oxidative stress25–27, Nppa and Nox4 respectively relative to Ywhaz (validated 
cardiac housekeeping gene). Nppa expression in mdx and B-PMO treated hearts was higher than their 
C57BL/10 counterparts (in unexercised and exercised mice; Fig. 7d). Nox4 expression was significantly 
raised in the mdx unexercised cohort. The mdx exercised and B-PMO cohorts were approximately 2-fold 
up-regulated (Fig. 7e). The elevated expression levels of these genes show that restoration of dystrophin 
in the diaphragm has not improved the cardiac phenotype of mice with dystrophic hearts.
Discussion
Our aim was to discern the effect of dystrophin restoration in the diaphragm on heart function in the mdx 
mouse model of DMD. A single intraperitoneal injection resulted in significant and widespread dystro-
phin in the diaphragm, with insignificant expression in other skeletal muscles, with the exception of the 
abdominal wall. However, whilst there was some reduction in diaphragmatic pathophysiology (reduced 
sarcolemmal damage), and marked improvement in diaphragm muscle function, dystrophin restoration 
in this respiratory muscle did not benefit cardiac function or pathophysiology, with or without exercise. 
1-way ANOVA
2-way 
ANO-
VA
C57unex SEM mdxunex SEM B-PMOunex SEM C57ex SEM mdxex SEM B-PMOex SEM
Interac-
tion
LV/
BW
Average 
Mass 3.75 ± 0.20 3.43 ± 0.08 3.26 ± 0.09 4.04 ± 0.25 3.60 0.14 3.37 ± 0.09 N/S
End 
Diastolic 
Volume
1.96 ± 0.14 1.77 ± 0.05 1.74 ± 0.06 2.03 ± 0.19 1.80 0.12 1.81 ± 0.08 N/S
End 
Systolic 
Volume
0.74 ± 0.12 0.65 ± 0.08 0.72 ± 0.03 0.74 ± 0.18 0.87 0.15 0.72 ± 0.07 N/S
Stroke 
Volume 1.22
ΔΔooo ± 0.04 1.12o ± 0.04 1.02**□□□ ± 0.04 1.29+ΔΔΔooox ± 0.04 0.93***+□□□ 0.05 1.09□ ± 0.04 0.002
Cardiac 
Output 0.52
+ΔΔoox ± 0.02 0.42*□□ ± 0.03 0.42**□□ ± 0.02 0.53++ΔΔoox ± 0.02 0.41□□** 0.02 0.44*□ ± 0.01 N/S
LV% Ejection Fraction 64 ± 2.7 64 ± 3.6 59 ± 0.9 66 ± 3.8 54 5.1 61 2.2 N/S
RV/
BW
End 
Diastolic 
Volume
1.64 ± 0.04 1.53 ± 0.05 1.64 ± 0.08 1.66 ± 0.05 1.66 0.05 1.68 ± 0.09 N/S
End 
Systolic 
Volume
0.45ΔΔΔooo ± 0.02 0.55oo ± 0.03 0.67***□□ ± 0.03 0.45ΔΔooo ± 0.04 0.74***□□□++ 0.04 0.67 ± 0.08 0.05
Stroke 
Volume 1.18
+Δoo ± 0.04 0.98*□ ± 0.04 0.97*□ ± 0.06 1.21+Δoox ± 0.06 0.92**□□ 0.04 1.01□ ± 0.04 N/S
Cardiac 
Output 0.50
+++ΔΔox ± 0.02 0.37***□□ ± 0.03 0.40**□ ± 0.02 0.50++Δox ± 0.02 0.40*□ 0.02 0.40*□ ± 0.01 N/S
RV% Ejection Fraction 72
+ΔΔΔooo ± 1.01 64*o ± 1.74 59***□□ ± 1.37 72ΔΔoo ± 2.57 55***+□□ 1.92 61.00 ± 3.35 0.02
BPM Heart Rate 427 ± 15.4 373 ± 20.2 376 ± 13.2 410 ± 11.0 428 12.2 401 ± 8.6 0.04
Gram Body Weight 32.4
Δo ± 0.78 32.4Δo ± 1.20 35.9*+□□□ ± 0.66 29.6ΔΔΔooo ± 0.72 35.9*+□□□ 0.50 32.60 ± 0.79 < 0.001
Table 1. Cardiac function parameters measured by cine-MRI for mdx, C57BL/10 and B-PMO treated 
cohorts. All parameters are presented relative to body weight (BW). Note: The exceptions to this were 
the ejection fraction which is represented as a percentage and heart rate calculated as beats per minute 
(BPM). Weights are in grams. Statistical significance was determined using one- way ANOVA followed by 
Tukey post-hoc test (TUANOVA). Games-Howell post-hoc test was also performed to correct for variance 
heterogeneity (GHANOVA). Each cohort is compared to all other cohorts. *significantly different to C57unex, 
+significantly different to mdxunex, Δsignificantly different to B-PMOunex, □significantly different to C57ex, 
osignificantly different to mdxex and xsignificantly different to B-PMOex. Number of symbols denotes 
significance i.e. *** p < 0.001, ** p < 0.01, * p < 0.05. N = 10 for each cohort. Two-way ANOVA was also 
performed to show the interaction effect between exercise and the mouse groups (mdx, C57BL/10 and 
B-PMO treated mice).
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In addition, restoration of dystrophin in the abdominal wall did not assist cardiac function either. This 
was surprising, as the diaphragm is the major respiratory muscle, and it was anticipated that restoring 
dystrophin would reduce vascular resistance and pulmonary hypertension10,17,28.
The outcome of this investigation contrasts with that of the study by Crisp et al.18, which utilised the 
same peptide-PMO conjugate. The distinct difference between these two studies is the delivery route i.e. 
intravenous versus intraperitoneal. Intravenous delivery restored high levels of dystrophin in the dia-
phragm, but also led to widespread expression in multiple other muscles including multiple respiratory 
muscles, as confirmed in this study (Fig. 1). Perhaps the intercostal and sternocleidomastoid respiratory 
muscles play a more important role than previously anticipated in overall respiratory function in the mdx 
mouse. Indeed the intercostal muscles are important for adequate inspiratory (external intercostals) and 
expiratory (internal intercostals) function29. Dystrophin is also present in smooth muscle and vascular 
endothelial cells in the microvasculature, where it regulates eNOS and thus NO handling28. However, in 
mdx mice, dystrophin is absent in vascular endothelial cells30–32 and the tunica media of blood vessels33, 
which may contribute to impaired NO signalling and therefore vasodilatory response28. The finding of 
dystrophin positive cells in blood vessels of liver sections has been demonstrated following very high 
and chronic dosing of PMO34. Perhaps intravenous administration with peptide-PMO restored dystro-
phin in the microvasculature, improving vasoregulation and thereby reducing vascular resistance. This 
theory of poor vasoregulation is supported by emerging evidence that mdx mice function under hypoxic 
conditions35,36.
Conversely, in the present study when intraperitoneal injection was used, dystrophin may not have 
been present in most respiratory muscles or the microvasculature. Therefore inspiratory and expiratory 
function may have been impaired due to the absence of dystrophin in respiratory muscles, particularly 
the intercostal muscles. Alternatively the absence of dystrophin in the vasculature may have led to poor 
vasoregulation, thus aggravating vascular resistance.
The increase in workload during exercise interestingly resulted in a reduction of dystrophin protein in 
the diaphragm. This may be due to several factors such as the inability to fully protect the muscle from 
Figure 5. Cardiac function parameters measured by cine-MRI in exercised mouse cohorts. Scatter plot 
graphs illustrating individual mouse values, mean and standard error of the mean (SEM) for left ventricular 
(LV) and right ventricular (RV) parameters relative to body weight. Note: The exception to this is the 
ejection fraction which is represented as a percentage (it is a volumetric fraction). Cardiac function in 
B-PMO and mdx was worse than C57BL/10 mice. Statistical significance was determined using ANOVA 
followed by Tukey post-hoc test or Games-Howell post-hoc test to correct for variance heterogeneity. 
(***p < 0.001, **p < 0.01, *p < 0.05). N = 10 for each cohort.
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increased workload, a potentially less stable transcript, or that the exercise regimen was initiated prior 
to the administration having a physiological effect. In addition, this emphasises the importance of mon-
itoring active patients who may require more frequent treatment administrations. This is also important 
given that current oligonucleotide chemistries undergoing clinical trial have demonstrated low systemic 
delivery and no restoration of dystrophin in cardiac muscle13–16. This highlights concerns pertaining to 
increased activity in patients.
The data demonstrate that restoration of dystrophin in the diaphragm markedly improved muscle 
function and reduced pathophysiology, yet did not have a beneficial effect on cardiorespiratory function. 
The diaphragm is a major respiratory muscle and therefore a major muscle to target. However restora-
tion of dystrophin in this muscle alone is only likely to confer cardiorespiratory benefit when coupled 
with restoration in respiratory muscles and, of course, in the heart itself. Indeed there are peptide-PMO 
modalities that are capable of targeting the heart such as Pip-PMOs37,38. In short, this study shows that 
targeting a single muscle or organ to treat the systemic disease DMD is insufficient. Instead it empha-
sises the importance of a body-wide treatment and work to find a therapy and delivery strategy that will 
restore dystrophin in particularly difficult to target organs.
Materials and Methods
Synthesis of peptide-PMO conjugates. The PMO sequence (5’-GGCCAAACCTCGGCTTAC 
CTGAAAT-3′ ) was purchased from Gene Tools LLC. B peptide (RXRRBRRXRRBRXB) was conjugated 
to PMO at the 3′ end via an amide linkage by the method previously described37. The B-PMO conjugate 
was purified by HPLC and was analysed by MALDI-TOF mass spectrometry. Peptide-PMO conjugates 
were dissolved in sterile water and filtered through a 0.22 μ m cellulose acetate membrane before use.
Animals and intraperitoneal injections. All procedures with the exception of diaphragm phys-
iology were authorized and approved by the University of Oxford ethics committee and UK Home 
Office (project licence 30/2907, protocol 19b2). These procedures were carried out in the Biomedical 
Sciences Unit, University of Oxford, in accordance with ‘Laboratory Animal Handbooks NO.14; The 
Design of Animal Experiments (2010)’. Diaphragm physiology was conducted in the animal facility at 
the Royal Veterinary College (RVC) under Home Office Licence and with the approval of the RVC 
Figure 6. In vitro assessment of muscle function in B-PMO treated diaphragms. Mdx mice received 
a single intraperitoneal injection of B-PMO and age, sex and litter-mate matched mdx mice were used 
as untreated controls. Three weeks post-treatment diaphragms were removed and muscle function was 
assessed in vitro. (a) Force-frequency curves showing specific isometric force production in both groups 
(N/cm2). A significant improvement in tetanic force was observed in diaphragm strips of B-PMO treated 
mice compared to untreated controls (stimulation frequencies 30-180Hz). In addition, an 88% improvement 
in maximal specific isometric force production was noted in B-PMO treated diaphragms (13.94 ± 0.69 
N/cm2) compared to the control group (7.4 ± 1.26 N/cm2). (b) Using an eccentric contraction protocol, 
B-PMO treated diaphragms had significant protection against eccentric contraction-induced muscle damage 
from eccentric contraction number 4 through to 10. A final tetanic force drop of 6.7 ± 0.87% compared to 
baseline was noted in B-PMO treated diaphragms, whilst control diaphragms exhibited a greater force loss 
of 18.6 ± 2.55%. Statistical significance was determined using Two-way repeated-measure ANOVA with 
Bonferroni’s post-hoc test, (*p = < 0.05), N = 7/8.
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Ethics committee. Male mdx mice (21 weeks of age) received a single intraperitoneal injection of B-PMO 
(19 mg/kg) prepared in 0.9% saline solution.
Exercise Regimen. An Exer 3/6 treadmill (Columbus Instruments, USA) was used for the exercised 
cohorts. The exercise regimen started at 21 weeks of age (1 day after B-PMO administration for treated 
cohort) and mice were exercised every second day for 3 weeks (10 exercised bouts in total). Mice were 
allowed 2 minutes for familiarisation. The exercise regimen for the first 2 exercise days was initiated at 
5 m/min and gradually increased in 1 m/min increments to 12 m/min, over a 45 minute period. For the 
following 2 exercise sessions, the speed was kept between 10 and 12 m/min, and for the remaining ses-
sions (6 bouts) a speed of 12 m/min was maintained for the full 45 minute exercise period.
Cine-MRI. All mice underwent cardiac cine-MRI at 24 weeks of age, as previously described39. Mice 
were anaesthetised using isoflurane and placed in the supine position into a purpose built cradle. ECG 
electrodes were inserted into the forepaws of the mouse and the respiration loop was taped across the 
abdomen. Once the mouse was secured, with a stable ECG measurement, the cradle was lowered into 
a vertical-bore, 11.7T MR system (Magnex Scientific, Oxon, UK) with a 40 mm birdcage coil (Rapid 
Biomedical, Wurzburg, Germany). Images were acquired using a Bruker console running Paravision 
2.1.1 (Bruker Medical, Ettlingen, Germany). The left and right ventricles were imaged by taking a contig-
uous stack of cine images in 1 mm increments. Images were analysed using ImageJ software (NIH Image, 
Bethesda, MD). The epicardial and endocardial borders were outlined using the ImageJ free-hand tool 
at end-diastole and end-systole.
Figure 7. Quantification of Evan’s blue dye leakage in diaphragm, heart and tibialis anterior muscles 
and gene expression of markers for injury in the hearts of exercised and unexercised C57BL/10, mdx 
and B-PMO treated mice. (a-c) Evans blue leakage was quantified by calculating the surface area of stained 
cells relative to total surface area of section. Scatter plot graphs of Evans blue staining illustrating individual 
mouse values, mean and standard error of the mean (SEM). Evans blue leakage was pronounced in 
diaphragm of mdx mice, and tibialis anterior of exercised mdx and B-PMO mice. No statistical significance 
between cohorts for heart. N = 3–4 for each cohort. Quantitative real time (RT-q)PCR for the expression of 
Nppa (d) and Nox4 (e) relative to Ywhaz in heart, normalised to C57BL/10 unexercised cohort. Expression 
of Nppa was elevated in B-PMO and mdx cohorts, and Nox4 elevated in mdx unexercised cohort. N = 8 
for each cohort. Statistical significance was determined using one-way ANOVA, Tukey post-hoc test 
(***p < 0.001, **p < 0.01, *p < 0.05).
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Following MRI, mice and were sacrificed by CO2 inhalation, and muscles and other tissues harvested 
and snap-frozen in cooled isopentane before storage at − 80 °C.
Diaphragm Physiology. For details of diaphragm muscle physiology, see Supplementary Materials 
online.
Evans Blue administration. Three to 4 mice from each cohort received a 1% Evans blue dye (10 μ l/
gram of mouse; Sigma) intraperitoneal injection. Mice were sacrificed 20 hours later and the TA, dia-
phragm and heart tissues were collected. These tissues were sectioned (8 μ m), soaked in acetone for 
10 minutes, rinsed with PBS and mounted. Evans blue infiltration was visualised using a Leitz DM RBE 
fluorescent microscope (Leica). The entire section was imaged using Axiovision Rel 4.7 Software (Zeiss). 
Images were manually reassembled and the surface area of Evans blue staining was calculated using the 
threshold function of ImageJ software.
Immunohistochemistry and quantification. Transverse sections of tissue samples were sectioned 
(8 μ m thick) and co-stained with rabbit-anti-dystrophin (Abcam) and rat anti-laminin (Sigma) and 
probed using goat-anti-rabbit IgG Alexa 594 and goat-anti-rat IgG 488 secondary antibodies respectively 
(Invitrogen). Dystrophin restoration was quantified by acquiring 4 representative images of dystrophin 
staining and the correlating laminin field for each section, using a Leitz DM RBE fluorescent microscope 
(Leica) and Axiovision Rel 4.7 Software (Zeiss). Using the ImagePro software (MediaCybernetics), 10 
regions of interest were randomly allocated on the laminin image which was overlaid on the correspond-
ing dystrophin image to attain the minimum and maximum fluorescence intensity for each treatment. 
Data were extrapolated and normalised to C57BL/10 as previously described37.
RT-PCR and RT-qPCR of dystrophin in mdx mouse tissues. Total RNA was extracted using 
TRIzol reagent (Invitrogen) as described in the manufacturer’s instructions. For each RT-PCR reaction, 
400 ng of RNA template was used in a 50 μ l reverse transcription reaction using One Step RT-PCR Kit 
(QIAGEN) and gene specific primers as previously described37. Two microlitres of cDNA was amplified 
in a 50 μ l nested PCR (QIAGEN PCR kit).
For quantitative analysis of exon skipping levels, 1 μ g of RNA was reverse transcribed using the High 
Capacity cDNA RT Kit (Applied Biosystems) according to manufacturer’s instructions. RT-qPCR anal-
ysis was carried out using 25 ng cDNA template and amplified with Taqman Gene Expression Master 
Mix (Applied Biosystems) on a StepOne Plus Thermocycler (Applied Biosystems). Levels of Dmd exon 
23 skipping were determined by multiplex qPCR of FAM-labelled primers spanning Exon 20–21 (Assay 
Mm.PT.47.9564450, Integrated DNA Technologies) and HEX-labelled primers spanning Exon 23–24 
(Mm.PT.47.7668824, Integrated DNA Technologies). The percentage of Dmd transcripts lacking exon 23 
was determined by normalising Dmd exon 23–24 amplification levels to Dmd exon 20–21 levels.
RT-qPCR of Nox4 and Nppa in mdx mouse hearts. For the RT-qPCR of injury markers, 1 μ g 
of RNA was reverse transcribed using a High Capacity cDNA Synthesis kit (Applied Biosystems). The 
cDNA was diluted and run using gene specific primers sets (Nppa Assay Mm.PT.58.8820983, Nox4 Assay 
Mm.PT.58.12973594.g, Integrated DNA Technologies) and TaqMan probe set (Applied Biosystems) on 
the StepOne Plus Real-Time PCR system (Applied Biosystems). Samples were normalised relative to the 
house-keeping gene, Ywhaz (Assay Mm.PT.39a.22214831, Integrated DNA Technologies).
Protein extraction and western blot. Tissue sample were homogenised and quantified (Bradford 
assay; Sigma) as previously described37. Ten to 15 μ g of untreated and treated mdx protein, and between 
50% and 5% of C57BL/10 protein (see Fig. 2 for percentage loading for each tissue) were loaded onto 
3-8% Tris-Acetate gels (Invitrogen). Protein gels were run for 110 minutes and blotted onto PVDF mem-
brane. Membranes were probed for dystrophin using DYS1 (Novocastra) and loading control, vincu-
lin (Sigma). Both primary antibodies were detected using IRDye 800CW goat-anti mouse IgG (Licor). 
Western blots were imaged (LiCOR Biosciences) and analysed using the Odyssey imaging system.
Statistical Analysis. All values reported are mean ± standard error of the mean (SEM). Students 
T-test was used to compare dystrophin protein levels (western blot) in B-PMO unexercised and exercised 
cohorts. For MRI, Evans blue staining and RT-qPCR, all statistically significant values were determined 
using a one-way ANOVA followed by a Tukey post-hoc test. For MRI analysis, Games-Howell post-hoc 
test was also performed to correct for variance heterogeneity. Two-way ANOVAs were also performed on 
MRI data to determine interactions between exercise and mouse cohorts. The statistical significance for 
the diaphragm physiology was determined using Two-way repeated-measure ANOVA with Bonferroni’s 
post-hoc test.
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